Ind Swift Laboratories
Ind-Swift Laboratories Ltd
- P/E
- 55.06
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 4.86%
- Debt to Equity
- 0.01
- EPS (TTM)
- ₹6.73
- Book Value
- ₹169.44
- Market Cap
- —
- P/E (TTM)
- 55.06
- P/B
- 2.19
- ROE
- 4.02%
- Dividend Yield
- 0.00%
- EBITDA
- ₹93.80 Cr
- 52W High
- ₹426.60
- 52W Low
- ₹87.15
- Day Range
- ₹345.50 – ₹373.00
- Volume
- 6,85,300
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Ind Swift Laboratories (this company) | ₹370.55 | 55.06 | ₹3,098 Cr | 2.19 | 0.00% | 4.02% | 4.86% | ₹665 Cr | ₹58 Cr |
| Median 8 companies | ₹1,587.70 | 46.94 | ₹1,25,337 Cr | 4.57 | 0.44% | 16.25% | 16.65% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 20
- Poor
- Returns, margins, earnings quality 22% weight
- Valuation
- 40
- Weak
- Cheap vs sector & own history 24% weight
- Growth
- 99
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 84
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 97
- Strong
- Trend strength, vol-adjusted 12% weight
- Ownership
- 56
- Good
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
3- Company has reduced debt.
- Company is almost debt free.
- Company is expected to give good quarter
Weaknesses
6- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -6.14% over past five years.
- Company has a low return on equity of 6.74% over last 3 years.
- Earnings include an other income of Rs.44.1 Cr.
- Debtor days have increased from 88.1 to 112 days.
- Working capital days have increased from 91.0 days to 156 days
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 1 | 7 | 11 |
| Oscillators | Bullish | 0 | 7 | 2 |
| Moving Averages | Strong Bullish | 1 | 0 | 9 |
Oscillators
Bullish
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 51.60
- Neutral
- MACD (12,26,9)
- −1.42
- Bullish
- SMA (50)
- 371.66
- Bearish
- SMA (200)
- 219.10
- Bullish
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | −0.06% |
|---|---|
| 5Y | −6.14% |
| 3Y | −18.68% |
| 1Y | +13.07% |
| TTM | +53.94% |
Net profit
| 10Y | Turned to profit |
|---|---|
| 5Y | Turned to profit |
| 3Y | −3.60% |
| 1Y | −82.80% |
| TTM | −74.34% |
Operating cash flow
| 10Y | Turned negative |
|---|---|
| 5Y | Turned negative |
| 3Y | Turned negative |
| 1Y | Outflow widened by ₹39 Cr |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | −9.15 pp |
|---|---|
| 5Y | −13.30 pp |
| 3Y | −11.73 pp |
| 1Y | +8.46 pp |
| TTM | +14.43 pp |
Revenue by year
| Mar 2017 | ₹716 Cr |
|---|---|
| Mar 2018 | ₹765 Cr |
| Mar 2019 | ₹757 Cr |
| Mar 2020 | ₹780 Cr |
| Mar 2021 | ₹891 Cr |
| Mar 2022 | ₹1,039 Cr |
| Mar 2023 | ₹1,207 Cr |
| Mar 2024 | ₹1,281 Cr |
| Mar 2025 | ₹574 Cr |
| Mar 2026 | ₹649 Cr |
Net profit by year
| Mar 2017 | −₹39.00 Cr |
|---|---|
| Mar 2018 | ₹22.00 Cr |
| Mar 2019 | ₹29.00 Cr |
| Mar 2020 | −₹21.00 Cr |
| Mar 2021 | −₹3.00 Cr |
| Mar 2022 | −₹2.00 Cr |
| Mar 2023 | ₹48.00 Cr |
| Mar 2024 | ₹421 Cr |
| Mar 2025 | ₹250 Cr |
| Mar 2026 | ₹43.00 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 310 | 290 | 288 | 529 | 33 | 12 | 129 | 138 | 153 | 153 | 151 | 170 | 191 | 240 |
| Expenses | 250 | 224 | 236 | 437 | 43 | 24 | 135 | 147 | 149 | 151 | 147 | 149 | 158 | 195 |
| Operating Profit | 60 | 66 | 52 | 91 | −10 | −12 | −7 | −9 | 4 | 1 | 4 | 21 | 33 | — |
| OPM % | 19% | 23% | 18% | 17% | −29% | −99% | −5% | −7% | 2.4% | 1% | 2.8% | 12% | 17% | — |
| Other Income | 6 | 7 | 7 | 458 | 11 | 13 | 16 | 220 | 15 | 18 | 22 | −3 | 7.65 | — |
| Interest | 20 | 21 | 21 | 3 | 0 | 0 | 10 | −27 | 1 | 2 | 1 | −2 | 1 | 1 |
| Depreciation | 14 | 13 | 14 | 20 | 0 | 0 | 6 | 7 | 7 | 7 | 9 | 8 | 8 | 8 |
| PBT | 32 | 39 | 24 | 527 | 1 | 1 | −7 | 230 | 10 | 10 | 16 | 12 | 33 | 43 |
| Tax % | 45% | 18% | 19% | 6% | −3% | 31% | −16% | 4% | 17% | 22% | 42% | −26% | 25% | 21% |
| Net Profit | 17 | 32 | 19 | 494 | 1 | 0 | −5 | 222 | 9 | 8 | 10 | 15 | 25 | 34 |
| EPS (₹) | 2.92 | 5.36 | 3.29 | 83.55 | 0.16 | 0.07 | −0.93 | 36.67 | 1.45 | 0.98 | 1.17 | 1.74 | 2.84 | — |
Sep 2026: from the results filed on 29 Oct 2026, ahead of the full statement, so some rows are blank.
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 660 | 653 | 716 | 765 | 757 | 780 | 891 | 1,039 | 1,207 | 1,281 | 574 | 649 | 665 |
| Expenses | 571 | 546 | 610 | 631 | 630 | 635 | 709 | 837 | 978 | 1,029 | 581 | 602 | 605 |
| Operating Profit | 89 | 107 | 106 | 134 | 126 | 144 | 183 | 202 | 229 | 252 | −7 | 47 | 60 |
| OPM % | 13% | 16% | 15% | 18% | 17% | 19% | 21% | 19% | 19% | 20% | −1.2% | 7% | 9% |
| Other Income | −31 | 1 | 15 | 16 | 120 | 33 | 23 | 37 | 7 | 434 | 292 | 36 | 44 |
| Interest | 117 | 106 | 88 | 28 | 92 | 107 | 100 | 96 | 92 | 51 | 3 | 1 | 1 |
| Depreciation | 84 | 85 | 88 | 87 | 104 | 90 | 87 | 131 | 57 | 53 | 24 | 31 | 32 |
| PBT | −143 | −83 | −55 | 36 | 50 | −20 | 18 | 13 | 87 | 582 | 258 | 51 | 71 |
| Tax % | −17% | −29% | −29% | 39% | 42% | 7% | 117% | 117% | 45% | 28% | 3% | 15% | — |
| Net Profit | −119 | −59 | −39 | 22 | 29 | −21 | −3 | −2 | 48 | 421 | 250 | 43 | 57 |
| EPS (₹) | −29.14 | −14.33 | −8.75 | 4.85 | 6.09 | −3.59 | −0.53 | −0.36 | 8.06 | 71.24 | 41.32 | 4.97 | 6.73 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 42 | 42 | 45 | 46 | 48 | 60 | 60 | 60 | 60 | 59 | 69 | 87 |
| Reserves | 553 | 476 | 486 | 507 | 540 | 581 | 544 | 541 | 622 | 872 | 1,104 | 1,297 |
| Borrowings | 1,413 | 1,457 | 1,242 | 1,083 | 1,148 | 1,031 | 1,005 | 953 | 862 | 17 | 33 | 18 |
| Other Liabilities | 236 | 240 | 364 | 387 | 188 | 198 | 210 | 247 | 280 | 217 | 232 | 271 |
| Total Liabilities | 2,244 | 2,215 | 2,138 | 2,023 | 1,924 | 1,870 | 1,818 | 1,801 | 1,824 | 1,165 | 1,438 | 1,673 |
| Fixed Assets | 1,117 | 1,099 | 1,042 | 934 | 914 | 843 | 753 | 630 | 587 | 8 | 273 | 304 |
| CWIP | 113 | 78 | 70 | 69 | 20 | 11 | 19 | 10 | 8 | 0 | 0 | 12 |
| Investments | 18 | 18 | 18 | 18 | 19 | 17 | 36 | 29 | 30 | 111 | 213 | 248 |
| Other Assets | 997 | 1,020 | 1,007 | 1,002 | 972 | 998 | 1,011 | 1,131 | 1,199 | 1,047 | 952 | 1,110 |
| Total Assets | 2,244 | 2,215 | 2,138 | 2,023 | 1,924 | 1,870 | 1,818 | 1,801 | 1,824 | 1,165 | 1,438 | 1,673 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 98 | 79 | 96 | 73 | −64 | 125 | 135 | 150 | 195 | −163 | −29 | −68 |
| Investing | −35 | −29 | −31 | −17 | −12 | −9 | −10 | 5 | −13 | −104 | −113 | −69 |
| Financing | −64 | −48 | −69 | −62 | 100 | −133 | −124 | −141 | −186 | 699 | 72 | 142 |
| Net Cash Flow | −1 | 3 | −4 | −6 | 23 | −17 | 1 | 14 | −4 | 431 | −69 | 5 |
| Free Cash Flow | 59 | 49 | 63 | 52 | −79 | 114 | 131 | 137 | 182 | −205 | −54 | −155 |
| CFO/EBITDA | 111 | 74 | 90 | 54 | −51 | 87 | 73 | 74 | 85 | −65 | 323 | −131 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 215 | 208 | 182 | 194 | 169 | 186 | 177 | 160 | 153 | 48 | 105 | 112 |
| Inventory Days | 312 | 368 | 305 | 291 | 284 | 313 | 301 | 288 | 242 | 6 | 145 | 187 |
| Days Payable | 120 | 137 | 91 | 118 | 114 | 123 | 111 | 118 | 113 | 52 | 140 | 185 |
| Cash Conversion Cycle | 407 | 439 | 396 | 367 | 339 | 375 | 367 | 330 | 282 | 2 | 110 | 114 |
| Working Capital Days | 141 | −26 | −97 | −49 | 217 | 248 | 253 | 253 | 234 | 2 | 115 | 156 |
| ROCE % | 1% | 2% | 2% | 4% | 4% | 5% | 7% | 7% | 13% | 20% | 3% | 5% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Ind Swift Laboratories insights
72 extracted metrics across FY12–FY27.
Documents
- 29 Mar 2024
- 7 Dec 2023
- 15 Sep 2023
- 8 Nov 2022
- 23 Dec 2021
- General announcements 30 Oct 2026
- General announcements 30 Oct 2026
Frequently Asked Questions about Ind Swift Laboratories
What does Ind-Swift Laboratories Ltd do?
Where is Ind-Swift Laboratories Ltd (INDSWFTLAB) listed?
Which sector does Ind-Swift Laboratories Ltd belong to?
What is the PE ratio of Ind-Swift Laboratories Ltd?
What is the 52-week high and low of Ind-Swift Laboratories Ltd?
What is the Return on Equity (ROE) of Ind-Swift Laboratories Ltd?
Company Information
Incorporated in 1995, Ind-Swift Laboratories Ltd is a pharmaceutical company focused on finished dosage formulations (FDF). Co. manufactures tablets, capsules, ointments, injectables, liquids and dry syrups across therapies including gynaecology, paediatrics, cardiology, diabetology and dermatology. Operations span domestic formulations and international markets through own brands, contract manufacturing and out-licensing.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/INDSWFTLAB.md for Ind-Swift Laboratories Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.